• slide
  • slide
  • slide

Our Solution

The Visica® Procedure is a minimally invasive cryoablation procedure. Over the past decade, the Visica® 2 Treatment System has proven to be safe and effective with thousands of successful cases completed. As an innovator in technology, Sanarus Technologies invented and patented the Visica 2 Treatment System low-pressure liquid nitrogen cryoablation device in 2007. In 2020, Sanarus was acquired by Hologic and is now a part of their comprehensive world-class breast-health portfolio.

View the procedure video here

Cryoablation Benefits

  • Under 30-minute procedure
  • Minimally invasive: conserves the shape of the breast
  • Excellent cosmesis: 3-5mm incision regardless of the tumor size
  • Requires only local anesthesia, patient is awake during the procedure
  • One day recover time: less time off work

Visica 2 Treatment System

  • Touch screen user interface
  • Automatically sets correct treatment algorithm based on lesion size
  • Guides the physician through procedural steps
  • Uses liquid nitrogen - universally available

ICE Probes

  • Tailored freeze zones for large and small lesions
  • Sharp trocar tip for ease of insertion
  • Ergonomically designed handle
  • Single use, sterile and disposable

Indications for Use: The Sanarus Visica 2 Treatment System is indicated for use in general surgery, gynecology and oncology. The System is designed to destroy tissue by the application of extreme cold temperatures. In addition, the System is intended for use in the following indications: General Surgery - ablation of breast fibroadenoma, localization of breast lesions. Gynecology - ablation of malignant neoplasia or benign dysplasia of the female genitalia. Oncology - ablation of cancerous or malignant tissue, ablation of benign tumors, and palliative intervention. See IFU for details.


  1. Simmons R, et al, A Phase 2 Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072, Ann Surg Oncol (2016) 23: 2438. doi:10.1245/s10434-016-5275-3.